EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

[177Lu]Lu-SSO110 with [68Ga]Ga-SSO120 companion imaging in patients with extensive-stage small-cell lung cancer (LuSato-1): a multicentre, phase 1, dose-escalation study

Giuseppe Cardaci, Richard Pham, Aviral Singh, Muhamad Khattak, Peter Lin, Abhijit Pal, Udit Nindra, Chong G Chew, Nimit Singhal, Stanley Ngai, Kenneth O’Byrne, Louise Emmett und 7 weitere

The Lancet Medical Imaging & Theranostics · 2026

DOI: 10.1016/j.lanmit.2026.100017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026. Verfasst von Giuseppe Cardaci und 18 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Outcomes for patients with extensive-stage small-cell lung cancer (ES-SCLC) remain suboptimal despite the addition of immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy. Somatostatin receptor 2 (SSTR2) is expressed in approximately 50% of SCLC lesions. SSTR2-targeted radiopharmaceutical therapy is safe and effective for other neuroendocrine tumours. Hence, we aimed to evaluate the safety and recommended phase 2 dose (RP2D) of [ 177 Lu]Lu-satoreotide tetraxetan ( 177 Lu-SSO110) with [ 68 Ga]Ga-satoreotide trizoxetan ( 68 Ga-SSO120) companion imaging in patients with ES-SCLC receiving maintenance ICIs.

Methods

LuSato-1 is a multicentre, open-label, phase 1, dose-escalation study conducted at six hospitals in Australia. Adults aged 18 years or older with histologically or cytologically and radiologically confirmed and previously untreated ES-SCLC, measurable disease according to the Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1), and an Eastern Cooperative Oncology Group performance status of 0 or 1 received four cycles of platinum (carboplatin or cisplatin), etoposide, and atezolizumab (1200 mg every 3 weeks) or durvalumab (1500 mg every 4 weeks) induction treatment. At the end of induction, patients without disease progression and who had SSTR2-positive disease on 68 Ga-SSO120 PET–CT were eligible for maintenance therapy with intravenous 177 Lu-SSO110 every 6 weeks for up to four cycles, with maintenance atezolizumab or durvalumab continued per standard schedules. The 177 Lu-SSO110 dose was escalated from 3·7 to 5·2 GBq following a Bayesian optimal interval design with a target dose-limiting toxicity (DLT) rate of 0·30 (30% of evaluable patients) per dose level. The primary outcomes were the safety of 177 Lu-SSO110 and 68 Ga-SSO120 and recommended phase 2 dose of 177 Lu-SSO110. Secondary outcomes included the investigator-assessed objective response rate by RECIST 1.1. Safety and activity analyses were done for all patients who received at least one cycle of 177 Lu-SSO110. The trial is registered with Australian New Zealand Clinical Trials Registry (ANZCTR; ACTRN12623000185662). The trial is active but closed for recruitment.

Findings

Between June 20, 2023, and June 30, 2025, 35 patients were enrolled into the induction phase. 20 (nine [45%] male and 11 [55%] female) of 35 patients did not have progressive disease, were deemed eligible for the maintenance phase, and received at least one dose of 177 Lu-SSO110 (median age 65·5 years [range 47–83]). The data cutoff for this analysis was Dec 8, 2025, and all patients were included in the analyses. The median follow-up time was 11·1 months (IQR 8·8–18·4). 15 (75%) of 20 patients had adverse events considered related to 177 Lu-SSO110 administration. Nine (45%) of 20 patients had grade 3 or 4 treatment-emergent adverse events attributed to 177 Lu-SSO110 administration. One DLT (grade 4 thrombocytopenia) occurred at the 5·2 GBq dose level. No adverse event was attributable to 68 Ga-SSO120, and no treatment-related deaths occurred. From the start of maintenance therapy, two (10%) of 20 patients had a further partial response, and 14 (70%) patients maintained stable disease. The recommended phase 2 dose of 177 Lu-SSO110 was determined to be 4·5 GBq.

Interpretation

Addition of 177 Lu-SSO110 to maintenance ICI therapy was generally safe and showed preliminary antitumour activity. These findings support further investigation of SSTR2-targeted radiopharmaceutical therapy in combination with ICIs in patients with ES-SCLC. Funding Ariceum International.

Zitieren

APA

Cardaci, G., Pham, R., Singh, A., Khattak, M., Lin, P., Pal, A., Nindra, U., Chew, C. G., Singhal, N., Ngai, S., O’Byrne, K., Emmett, L., Chin, V., Ramdave, S., Hicks, R., Preston, J. K., Jordaan, P., Gericke, G., & Arulananda, S. (2026). [177Lu]Lu-SSO110 with [68Ga]Ga-SSO120 companion imaging in patients with extensive-stage small-cell lung cancer (LuSato-1): a multicentre, phase 1, dose-escalation study. The Lancet Medical Imaging & Theranostics. https://doi.org/10.1016/j.lanmit.2026.100017

Vancouver

Cardaci G, Pham R, Singh A, Khattak M, Lin P, Pal A, et al. [177Lu]Lu-SSO110 with [68Ga]Ga-SSO120 companion imaging in patients with extensive-stage small-cell lung cancer (LuSato-1): a multicentre, phase 1, dose-escalation study. The Lancet Medical Imaging & Theranostics. 2026. doi:10.1016/j.lanmit.2026.100017

BibTeX
@article{Cardaci2026,
  author = {Cardaci, Giuseppe and Pham, Richard and Singh, Aviral and Khattak, Muhamad and Lin, Peter and Pal, Abhijit and Nindra, Udit and Chew, Chong G and Singhal, Nimit and Ngai, Stanley and O’Byrne, Kenneth and Emmett, Louise and Chin, Venessa and Ramdave, Shakher and Hicks, Rodney and Preston, Jessica K and Jordaan, Pierre and Gericke, Germo and Arulananda, Surein},
  title = {[177Lu]Lu-SSO110 with [68Ga]Ga-SSO120 companion imaging in patients with extensive-stage small-cell lung cancer (LuSato-1): a multicentre, phase 1, dose-escalation study},
  journal = {The Lancet Medical Imaging & Theranostics},
  year = {2026},
  doi = {10.1016/j.lanmit.2026.100017}
}
Kostenlos starten →